Home/Pipeline/CBN-101

CBN-101

Cystic Fibrosis

PreclinicalActive

Key Facts

Indication

Cystic Fibrosis

Phase

Preclinical

Status

Active

Company

Carbon Biosciences

About Carbon Biosciences

Carbon Biosciences is a private, preclinical-stage biotech leveraging its engineered parvovirus (parvovector) platform to create next-generation gene therapies. The company's initial focus is on cystic fibrosis, where its vector aims to deliver the full CFTR gene more effectively than current options. Founded in 2019 and backed by notable life science investors, Carbon is positioning its platform to address a range of genetic disorders with high unmet need. Its approach seeks to improve upon AAV vectors by allowing for larger transgenes and potentially redosable administration.

View full company profile

Therapeutic Areas

Cystic Fibrosis Genetic Diseases

Other Cystic Fibrosis Drugs

Drug	Company	Phase	Status
CB-280	Calithera Biosciences	Preclinical/Phase 1	Discontinued
Ensifentrine	Verona Pharma	Phase 2	Under MSD
ALTA Drug Series	Alteron Therapeutics	Preclinical	Research
ColiFin®	Spexis	Marketed (EU)	Active
Cystic fibrosis (CRISPR)	GeneToBe	Discovery	Active
Cystic fibrosis (undisclosed)	GeneToBe	Early Discovery	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
Targeted Lung Delivery	Nanite	Pre-clinical	Active
CFTR 100+ Panel	Agena Bioscience	Commercial	Active
RIG-301 CFTR	RIGImmune	Pre-clinical	Active
RESP® Biosensor Evaluation (with Rutgers Health)	Strados Labs	Research Study	Active
KIT2014	Kither Biotech	Phase 2	Active